Clinical trials
Lymphoma, T-Cell, Peripheral trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Unknown status | 3 |
| Active, not recruiting | 2 |
| Recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Samsung Medical Center | 3 |
| AstraZeneca | 2 |
| Chonnam National University Hospital | 2 |
| Solasia Pharma K.K. | 2 |
| Acrotech Biopharma Inc. | 1 |
| Affimed GmbH | 1 |
| Associazione Angela Serra per la ricerca sul cancro | 1 |
| Boryung Pharmaceutical Co., Ltd | 1 |
| Daiichi Sankyo | 1 |
| Dizal Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, T-Cell, Peripheral | 22 |
| Recurrence | 4 |
| Lymphoma, Extranodal NK-T-Cell | 3 |
| Lymphoma | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Lymphoma, T-Cell | 2 |
| Enteropathy-Associated T-Cell Lymphoma | 1 |
| Febrile Neutropenia | 1 |
| Hodgkin Disease | 1 |
| Immunoblastic Lymphadenopathy | 1 |
Trials
Showing 51 to 22 of 22. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.